Das Klinikum

Prof. Dr. med. Peter Lang

Prof. Dr. med. Peter Lang

Komm. med.-wiss. Direktor Abteilung I, Bereichsleiter Stammzelltransplantation

Kontakt

Telefonnummer: 07071 29-85770

Faxnummer: 07071 29-5481

E-Mail-Adresse: peter.lang@med.uni-tuebingen.de

Klinik / Institut / Zentrum

  • Pädiatrische Hämatologie / Onkologie, Stammzelltransplantation, Immuntherapie

  • Clinical and Research interests

    Stem cell transplantation and ex vivo graft manipulation procedures: •CD34 selection, •T cell depletion strategies, •transfer of antigen specific T cells) Immunotherapy: • Antibody-based immunotherapy • Peptide vaccination • Adoptive transfer of T cells and NK cells • Clinical studies. • Our research focusses on the development and improvement of new and existing immunotherapeutic approaches for both hematological malignancies and solid tumors in pediatric patients. Of special interest is the translation into the clinical setting, reflected by a broad range of clinical studies. Currently, our antibody-based studies include antibodies fused to stimulating cytokines (immunocytokines) and a tri-specific antibody construct directed against tumor antigens like CD276 (B7-H3), GD2 or CD33/123, both recruiting effector NK cells to elicit ADCC. A bi-specific construct engaging effector T cells is under investigation as well. Furthermore, in an investigator-initiated trial (NCT02258815) which is currently continued in the form of a registry, we are evaluating the addition of an anti-GD2 antibody post-alloHSCT in patients with relapsed neuroblastoma. This approach significantly increased EFS in neuroblastoma patients. Another study which involves an optimized anti-CD19 mAb for treatment of BCP-ALL, was recently initiated. Within a compassionate use program at our institution this antibody has already proven to significantly reduce MRD after haploHSCT. In our IVAC-ALL-1 study in relapsed ALL patients, patient-individualized peptide vaccines were used to stimulate T cells. Subsequent immunomonitoring revealed immunogenicity of selected peptides and induction of specific T cell responses in these patients. Based on these promising results and analogous to our study, the IVAC-RCC trial was recently initiated in Heilbronn for which we will perform immunomonitoring of T cell responses. Furthermore, we are evaluating the use of autologous transgenic T cells designed to specifically target CMV, ADV and EBV antigens. An adoptive transfer of such T cells might be of great importance during immune reconstitution in the post autoHSCT setting which is commonly characterized with an increased risk for reactivation of latent viral infections.

  • Stem cell transplantation and ex vivo graft manipulation procedures: •CD34 selection, •T cell depletion strategies, •transfer of antigen specific T cells)
  • Immunotherapy: • Antibody-based approaches (neuroblastoma, leukemia) • Peptide vaccination • Adoptive transfer of T cells and NK cells • Clinical studies.
  • h-index: 54
  • impact factor (cumulative): 1994
  • Total number of publications: 282
  • 1999 – 2009
    Senior physician (Specialist for Pediatric Hematology/Oncology)
  • 2005 – present
    Medical director of the laboratory for graft engineering and immunophenotyping, University Children’s Hospital Tübingen
  • 2009 – present
    Associate Professor and head of the Pediatric stem cell transplantation unit, University Children’s Hospital Tübingen.
  • 2012 – 03/2021
    Deputy medical Director of the Department of General Pediatrics and Hematology/ Oncology, University Children’s Hospital Tübingen.
  • 04/2021 – 04/23
    Acting Medical Director of the Department of General Pediatrics and Hematology/ Oncology, University Children’s Hospital Tübingen
  • 04/23-8/25
    Deputy medical Director of the Department of General Pediatrics and Hematology/ Oncology, head of stem cell transplantation unit
  • 09/25-present
    Acting medical-scientific Director Department I
  • Schober S, Doring M, Lang P, Schulte J, Olivieri M, Icheva V. Hematopoietic stem cell transplantation in a newborn suffering from severe combined immunodeficiency and severe hemophilia A: a case report and review of the literature. (2025) Res Pract Thromb Haemost. 9, 102842.
  • Zirngibl F, Gebert P, Materne B, Launspach M, Kunkele A, Hundsdoerfer P, Cyrull S, Deubzer HE, Kuhl JS, Eggert A, Lang P, Oevermann L, von Stackelberg A, Schulte JH. Everolimus with or without Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis after Hematopoietic Stem Cell Transplantation in Children with Acute Kidney Injury: A Single-Center Retrospective Analysis. (2025) Transplant Cell Ther. 31, 257 e1- e14.
  • Launspach M, Mindermann A, Schulz J, Alasfar L, Cyrull S, Zirngibl F, Oevermann L, Kunkele A, Deubzer HE, von Bernuth H, Pruss A, Lang P, Bufler P, Eggert A, von Stackelberg A, Schulte JH. High Incidence and Impact of Suspected Exocrine Pancreatic Insufficiency in Patients Post-Hematopoietic Stem Cell Transplantation: A Single-Center Prospective Observational Study. (2025) United European Gastroenterol J. 13, 257-67.
  • Grunebach F, Haack TB, Doring M, Merz B, Petz A, Bauer C, Storz M, Lang P, Klein R. Deletion of the HLA-B Gene in One of the Inherited Haplotypes in a Northern European Family. (2025) HLA. 105, e70234
  • Flaadt T, Rehm J, Simon T, Hero B, Ladenstein RL, Lode HN, Grabow D, Nolte S, Crazzolara R, Greil J, Ebinger M, Abele M, Holzer U, Doring M, Schulte JH, Bader P, Schlegel PG, Eyrich M, Lang P, Klingebiel T, Handgretinger R. Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study. (2025) Cancers (Basel).
  • Dulovic A, Rabsteyn A, Remppis J, Gentzcke IKE, Mueller J, Tuecks N, Becker M, Junker D, Kaiser PD, Traenkle B, Rothbauer U, Walz JS, Peter A, Horber S, Ganzenmueller T, Iftner T, Stich M, Tonshoff B, Henneke P, Elling R, Debatin KM, Janda A, Schneiderhan-Marra N, Franz AR, Lang P, Renk H. Longitudinal analysis of humoral and cellular immunity in SARS-CoV-2 exposed families. (2025) Sci Rep. 15, 26041
  • Breidenbach M, Bader P, Attarbaschi A, Rossig C, Meisel R, Metzler M, Subklewe M, Mueller F, Schlegel PG, Teichert von Luttichau I, Bourquin JP, Escherich G, Cario G, Lang P, Coffey R, von Stackelberg A, Willier S, Strahm B, Peters C, Feuchtinger T. Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults. (2025) J Hematol Oncol. 18, 8
  • Amorelli G, Rabsteyn A, Maier CP, Trautner F, Holzer U, Schafer JF, Ebinger M, Handgretinger R, Nahnsen S, Rammensee HG, Lang P. Case Report: A neoantigen-targeting peptide vaccine combined with checkpoint inhibition induces tumor regression and long-term remission in a pediatric patient with metastatic hepatocellular carcinoma. (2025) Front Immunol. 16, 1674663.
  • Eichholz T, Heubach F, Arendt AM, Seitz C, Brecht IB, Ebinger M, Flaadt T, Süsskind D, Richter L, Hülsenbeck I, Zerweck L, Göricke S, Paulsen F, Dombrowski F, Flotho C, Schönberger S, Ketteler P, Schulte J, Lang P. Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3. (2024) Cancer Immunol Immunother. 73, 19.
  • Corbacioglu S, Lode H, Ellinger S, Zeman F, Suttorp M, Escherich G, Bochennek K, Gruhn B, Lang P, Rohde M, Debatin KM, Steinbach D, Beilken A, Ladenstein R, Spachtholz R, Heiss P, Hellwig D, Troger A, Koller M, Menhart K, Riemenschneider MJ, Zoubaa S, Kietz S, Jakob M, Sommer G, Heise T, Hundsdorfer P, Kuhnle I, Dilloo D, Schonberger S, Schwabe G, von Luettichau I, Graf N, Schlegel PG, Fruhwald M, Jorch N, Paulussen M, Schneider DT, Metzler M, Leipold A, Nathrath M, Imschweiler T, Christiansen H, Schmid I, Crazzolara R, Niktoreh N, Cario G, Faber J, Demmert M, Babor F, Frohlich B, Bielack S, Bernig T, Greil J, Eggert A, Simon T, Foell J. Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial. (2024) Lancet Oncol. 25, 922-32.
  • Atar D, Ruoff L, Mast AS, Krost S, Moustafa-Oglou M, Scheuermann S, Kristmann B, Feige M, Canak A, Wolsing K, Schlager L, Schilbach K, Zekri L, Ebinger M, Nixdorf D, Subklewe M, Schulte J, Lengerke C, Jeremias I, Werchau N, Mittelstaet J, Lang P, Handgretinger R, Schlegel P, Seitz CM. Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia. (2024) Leukemia 38, 2183-95
  • Flaadt T, Jaki C, Maier CP, Amorelli G, Klingebiel T, Schlegel PG, Eyrich M, Greil J, Schulte JH, Bader P, Handgretinger R, Lang P. Immune reconstitution after transplantation of autologous peripheral stem cells in children: a comparison between CD34+ selected and nonmanipulated grafts. (2024) Cytotherapy.
  • Laugwitz L, Mechtler TP, Janzen N, Oliva P, Kasper AR, Teunissen CE, Burger F, Janda J, Doring M, Weitz M, Lang P, Martin P, Beck-Woedl S, Chanson C, Essing MM, Shenker A, Haack TB, Schulte JH, Rosewich H, Streubel B, Kasper DC, Groeschel S. Newborn Screening and Presymptomatic Treatment of Metachromatic Leukodystrophy. (2024) N Engl J Med. 391, 1256-8.
  • Locatelli F, Lang P, Wall D, Meisel R, Corbacioglu S, Li AM, de la Fuente J, Shah AJ, Carpenter B, Kwiatkowski JL, Mapara M, Liem RI, Cappellini MD, Algeri M, Kattamis A, Sheth S, Grupp S, Handgretinger R, Kohli P, Shi D, Ross L, Bobruff Y, Simard C, Zhang L, Morrow PK, Hobbs WE, Frangoul H, Group CT-S. Exagamglogene Autotemcel for Transfusion-Dependent beta-Thalassemia. (2024) N Engl J Med. 390, 1663-76.
  • Bohm S, Wustrau K, Pachlopnik Schmid J, Prader S, Ahlmann M, Yacobovich J, Beier R, Speckmann C, Behnisch W, Ifversen M, Jordan M, Marsh R, Naumann-Bartsch N, Mauz-Korholz C, Honig M, Schulz A, Malinowska I, Hines M, Nichols KE, Gil-Herrera J, Talano JA, Crooks B, Formankova R, Jorch N, Bakhtiar S, Kuhnle I, Streiter M, Nathrath M, Russo A, Durken M, Lang P, Lindemans C, Henter JI, Lehmberg K, Ehl S. Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation. (2024) Blood. 143, 872-81.
  • Maier CP, Klose C, Seitz CM, Heubach F, Doring M, Meisel R, Schuster FR, Gruhn B, Keller F, Rabsteyn A, Arendt AM, Amorelli G, Eichholz T, Feuchtinger T, Martinius H, Nierkens S, Teltschik R, Schulte JH, Lengerke C, Handgretinger R, Lang P. Influence of ATLG Serum Levels on CD3/CD19-depleted Hematopoietic Grafts and on Immune Recovery in Pediatric Haplo-HSCT. (2024) Blood Adv
  • Arendt AM, Heubach F, Maier CP, Giardino S, Jung G, Kowalewski E, Rabsteyn A, Amorelli G, Seitz C, Schlegel P, Handgretinger R, Lang P. Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3). (2023) Cancer Immunol Immunother. 72, 3813-24.
  • Heinz AT, Calkoen FGJ, Derbich A, Miltner L, Seitz C, Doering M, Braun C, Atar D, Schumm M, Heubach F, Arendt AM, Schulz A, Schuster FR, Meisel R, Strahm B, Finke J, Heineking B, Stetter S, Silling G, Stachel D, Gruhn B, Debatin KM, Foell J, Schulte JH, Woessmann W, Mauz-Körholz C, Tischer J, Feuchtinger T, Handgretinger R, Lang P. Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation. Haematologica. 108, 2080-90
  • Eichholz T, Doring M, Giardino S, Gruhn B, Seitz C, Flaadt T, Schwinger W, Ebinger M, Holzer U, Mezger M, Teltschik HM, Sparber-Sauer M, Koscielniak E, Abele M, Handgretinger R, Lang P. Haploidentical hematopoietic stem cell transplantation as individual treatment option in pediatric patients with very high-risk sarcomas. (2023) Front Oncol. 13, 1064190.
  • Flaadt T, Ladenstein RL, Ebinger M, Lode HN, Arnardottir HB, Poetschger U, Schwinger W, Meisel R, Schuster FR, Doring M, Ambros PF, Queudeville M, Fuchs J, Warmann SW, Schafer J, Seitz C, Schlegel P, Brecht IB, Holzer U, Feuchtinger T, Simon T, Schulte JH, Eggert A, Teltschik HM, Illhardt T, Handgretinger R, Lang P. Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial. (2023) J Clin Oncol. JCO2201630.
  • Handgretinger R, Lang P. Could (should) we abandon total body irradiation for conditioning in children with leukemia. (2022) Blood Rev. 56, 100966
  • Handgretinger R, Arendt AM, Maier CP, Lang P. Ex vivo and in vivo T-cell depletion in allogeneic transplantation: towards less or non-cytotoxic conditioning regimens. (2022) Expert Rev Clin Immunol. 18, 1285-96
  • Maier C, Heubach F, Herrmann S, Kummerle P, Arendt A, Rabsteyn A, Fey GH, Peipp M, Lengerke C, Bethge W, Handgretinger R, Lang P. Effective lysis of MOLM-13 and AML blasts by triplebody spm-2 (cd123-16-33) in combination with subsets of nk cells. (2022) Bone Marrow Transplant. 57, 336-7.
  • Bethge WA, Eyrich M, Mielke S, Meisel R, Niederwieser D, Schlegel PG, Schulz A, Greil J, Bunjes D, Brecht A, Kuball J, Schumm M, Vucinic V, Wiesneth M, Bonig H, Westinga K, Biedermann S, Holtkamp S, Karitzky S, Malchow M, Siewert C, Handgretinger R, Lang P. Results of a multicenter phase I/II trial of TCRalphabeta and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients. (2022) Bone Marrow Transplant. 57, 423-30
  • Seitz, C. M., Eyrich, M., Greil, J., Schlegel, P., Feuchtinger, T., Bader, P., Ebinger, M., Schwarze, C. P., Schlegel, P. G., Schumm, M., Handgretinger, R. and Lang, P. (2018) Favorable immune recovery and low rate of GvHD in children transplanted with partially T cell-depleted PBSC grafts. Bone Marrow Transplant.
  • Thiel U, Schober SJ, Ranft A, Gassmann H, Jabar S, Gall K, von Lüttichau I, Wawer A, Koscielniak E, Diaz MA, Ussowicz M, Kazantsev I, Afanasyev B, Merker M, Klingebiel T, Prete A, Gruhn B, Bader P, Jürgens H, Dirksen U, Handgretinger R, Burdach S, Lang P. (2021) No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease. Bone Marrow Transplant doi: 10.1038/s41409-020-01200-x
  • Lang P, Eichholz T, Bakchoul T, Streiter M, Petrasch M, Bösmüller H, Klein R, Rabsteyn A, Lang AM, Adams C, Klingel K, Gessner M, Rosenberger P, Ruef P, Handgretinger R. (2020) Defibrotide for the Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 2 Pediatric Patients. J Pediatric Infect Dis Soc. 9(5):622-625. doi: 10.1093/jpids/piaa117.
  • Schlegel P, Lang AM, Matela M, Horrer A, Schilling A, Jochner A, Wiedenmann M, Seitz C, Doring M, Feuchtinger T, Heubach F, Rabsteyn A, Handgretinger R, Lang P. (2019) Ex vivo expansion of autologous, donor-derived NK-, gammadeltaT-, and cytokine induced killer (CIK) cells post haploidentical hematopoietic stem cell transplantation results in increased antitumor activity. Bone Marrow Transplant. 54 (Suppl 2):727-32.
  • llhardt, T., Toporski, J., Feuchtinger, T., Turkiewicz, D., Teltschik, H. M., Ebinger, M., Schwarze, C. P., Holzer, U., Lode, H. N., Albert, M. H., Gruhn, B., Urban, C., Dykes, J. H., Teuffel, O., Schumm, M., Handgretinger, R. and Lang, P. (2018) Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma. Biol Blood Marrow Transplant. 24, 1005-1012
  • Mainardi, C., Ebinger, M., Enkel, S., Feuchtinger, T., Teltschik, H. M., Eyrich, M., Schumm, M., Rabsteyn, A., Schlegel, P., Seitz, C., Schwarze, C. P., Muller, I., Greil, J., Bader, P., Schlegel, P. G., Martin, D., Holzer, U., Doring, M., Handgretinger, R. and Lang, P. (2018) CD34(+) selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. Br J Haematol. 180, 90-99
  • Teltschik, H. M., Heinzelmann, F., Gruhn, B., Feuchtinger, T., Schlegel, P., Schumm, M., Kremens, B., Muller, I., Ebinger, M., Schwarze, C. P., Ottinger, H., Zips, D., Handgretinger, R. and Lang, P. (2016) Treatment of graft failure with TNI-based reconditioning and haploidentical stem cells in paediatric patients. Br J Haematol. 175, 115-122.
  • Seidel, U. J., Schlegel, P., Grosse-Hovest, L., Hofmann, M., Aulwurm, S., Pyz, E., Schuster, F. R., Meisel, R., Ebinger, M., Feuchtinger, T., Teltschik, H. M., Witte, K. E., Schwarze, C. P., Rammensee, H. G., Handgretinger, R., Jung, G. and Lang, P. (2016) Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody. Mol Ther. 24, 1634-1643
  • Lang, P., Feuchtinger, T., Teltschik, HM., Schwinger, W., Schlegel, P., Pfeiffer, M., Schumm, M., Lang, AM., Lang, B., Schwarze, CP., Ebinger, M., Urban, C., Handgretinger, R.(2015) Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patients. Bone Marrow Transplant. 50 Suppl 2, 6-10
  • Schlegel, P., Feuchtinger, T., Nitschke-Gérard, C., Seidel, UJ., Lang, AM., Kyzirakos, C., Teltschik, HM., Ebinger, M., Schumm, M., Koscielniak, E., Handgretinger, R., Lang, P. (2015) Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing's sarcoma patients. Bone Marrow Transplant. 50 Suppl 2, 72-6.
  • Lang, P., Teltschik, H. M., Feuchtinger, T., Muller, I., Pfeiffer, M., Schumm, M., Ebinger, M., Schwarze, C. P., Gruhn, B., Schrauder, A., Albert, M. H., Greil, J., Urban, C. and Handgretinger, R. (2014) Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia. Br J Haematol. 165, 688-698
  • Illhardt, T., Ebinger, M., Schwarze, C. P., Feuchtinger, T., Furtwangler, R., Schlegel, P. G., Klingebiel, T., Greil, J., Beck, J. F., Handgretinger, R. and Lang, P. (2014) Children with Relapsed or Refractory Nephroblastoma: Favorable Long-term Survival after High-dose Chemotherapy and Autologous Stem Cell Transplantation. Klin Padiatr. 226, 351-356
  • Seidel, U. J., Vogt, F., Grosse-Hovest, L., Jung, G., Handgretinger, R. and Lang, P. (2014) γδ T Cell-Mediated Antibody-Dependent Cellular Cytotoxicity with CD19 Antibodies Assessed by an Impedance-Based Label-Free Real-Time Cytotoxicity Assay. Front Immunol. 5, 618
  • Pfeiffer, MM., Burow, H., Schleicher, S., Handgretinger, R., Lang, P. (2013) Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia. Front Oncol.3,99
  • Seidel, UJ., Schlegel, P., Lang, P. (2013) Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol. 4; 76
  • Pfeiffer, M., Schumm, M., Müller, I., Handgretinger, R., Lang, P. (2012) IL-15-stimulated CD3/CD19-depleted stem-cell boosts in relapsed pediatric patients after haploidentical SCT Leukemia 26, 2435-9.
  • Pfeiffer, M., Feuchtinger, T., Teltschik, HM., Schumm, M., Müller, I., Handgretinger, R., Lang, P. (2010) Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children. Haematologica. 95, 1381-1388
  • Feuchtinger, T., Richard, C., Joachim, S., Scheible, M.H., Schumm, M., Hamprecht, K., Martin, D., Jahn, G., Handgretinger, R., and Lang, P. (2008) Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J.Immunother. 31, 199-206
  • Lang, P., Barbin,K., Feuchtinger,T., Greil,J., Peipp,M., Zunino,S.J., Pfeiffer,M., Handgretinger,R., Niethammer,D. and Fey,G.H. (2004) Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effectors from pediatric patients transplanted with T cell depleted allografts. Blood, 15; 3982-3985
  • Lang, P., Handgretinger,R., Niethammer,D., Schlegel,P.G., Schumm,M., Greil,J., Bader,P., Engel,C., Scheel-Walter,H., Eyrich,M. and Klingebiel,T. (2003) Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. Blood, 101, 1630-1636
  • Schlegel, P., Teltschik, HM., Pfeiffer, M., Handgretinger, R., Schumm, M., Koscielniak, E., Feuchtinger, T., Klingebiel, T., Bader, P., Schlegel, PG., Greil, J., Lang, P. (2011) Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children. Best Pract Res Clin Haematol. 24, 443-52.
  • Lang, P., Pfeiffer, M., Teltschik, HM., Pflugrad, U., Feuchtinger, T., Ebinger, M., Klingebiel, T., Bader, P., Schlegel, P-G., Beck, J., Greil, J., Handgretinger, R. (2011) Natural Killer cell activity influences outcome after T cell depleted stem cell transplantation from matched unrelated and haploidentical donors. Best Pract Res Clin Haematol. 24, 403-11.
  • Feuchtinger, T., Opherk, K., Bicanic, O., Schumm, M., Grigoleit, GU., Hamprecht, K., Jahn, G., Handgretinger, R. and Lang, P. (2010) Dendritic cell vaccination in an allogeneic stem cell recipient receiving a transplant from a human cytomegalovirus (HCMV)-seronegative donor: induction of a HCMV-specific T(helper) cell response. Cytotherapy., 12, 945-950.
  • Rettinger, E., Schumm, M., Pfeiffer, M., Kuçi, S., Willasch, A., Handgretinger, R., Niethammer, D., Lang, P. (2010) Identification and selective depletion of alloreactive T-cells for adoptive immunotherapy. Lab Hematol. 16, 8-22.
  • Feuchtinger, T., Pfeiffer, M., Pfaffle, A., Teltschik, H.M., Wernet, D., Schumm, M., Lotfi, R., Handgretinger, R., and Lang, P. (2009) Cytolytic activity of NK cell clones against acute childhood precursor-B-cell leukaemia is influenced by HLA class I expression on blasts and the differential KIR phenotype of NK clones. Bone Marrow Transplant 43, 875-881
  • Lang, P. and Handgretinger, R. (2008) Haploidentical SCT in children: an update and future perspectives. Bone Marrow Transplant. 42 Suppl 2, S54-S59
  • Handgretinger, R. and Lang, P. (2008) The history and future prospective of haplo-identical stem cell transplantation. Cytotherapy 10, 443-451
  • Lang, P., Mueller, I., Greil, J., Bader, P., Schumm, M., Pfeiffer, M., Hoelle, W., Klingebiel, T., Heinzelmann, F., Belka, C., Schlegel, P.G., Kremens, B., Woessmann, W., and Handgretinger, R. (2008) Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients. Blood Cells Mol Dis 40, 33-39
  • Handgretinger, R., Chen, X., Pfeiffer, M., Mueller, I., Feuchtinger, T., Hale, G.A., and Lang, P. (2007) Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation. Ann.N.Y.Acad.Sci. 1106, 279-289
  • Pfeiffer, M., Schumm, M., Feuchtinger, T., Dietz, K., Handgretinger, R., and Lang, P. (2007) Intensity of HLA class I expression and KIR-mismatch determine NK-cell mediated lysis of leukaemic blasts from children with acute lymphatic leukaemia. Br.J.Haematol. 138, 97-100
  • Schumm, M., Feuchtinger, T., Pfeiffer, M., Hoelle, W., Bethge, W., Ebinger, M., Kuci, S., Handgretinger, R., and Lang, P. (2007) Flow cytometry with anti HLA-antibodies: a simple but highly sensitive method for monitoring chimerism and minimal residual disease after HLA-mismatched stem cell transplantation. Bone Marrow Transplant 39, 767-773
  • Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K, Handgretinger R, Peters C, Schuster FR, Beck R, Schumm M, Lotfi R, Jahn G, and Lang P. (2006) Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 134;64-76
  • Lang, P., Pfeiffer, M., Muller, I., Schumm, M., Ebinger, M., Koscielniak, E., Feuchtinger, T., Foll, J., Martin, D., and Handgretinger, R. (2006) Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klin.Padiatr. 218, 321-326
  • Schumm, M., Handgretinger, R., Pfeiffer, M., Feuchtinger, T., Kuci, S., Faul, C., Vogel, W., Bethge, W., and Lang, P. (2006) Determination of residual T- and B-cell content after immunomagnetic depletion: proposal for flow cytometric analysis and results from 103 separations. Cytotherapy. 8, 465-472
  • Feuchtinger, T., Lucke, J., Hamprecht, K., Richard, C., Handgretinger, R., Schumm, M., Greil, J., Bock, T., Niethammer, D., and Lang, P. (2005) Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br.J.Haematol. 128, 503-509
  • Feuchtinger, T., Richard, C., Pfeiffer, M., Neuhauser, F., Lucke, J., Handgretinger, R., Greil, J., Bader, P., Klingebiel, T., Schlegel, P.G., Jahn, G., Niethammer, D., and Lang, P. (2005) Adenoviral infections after transplantation of positive selected stem cells from haploidentical donors in children: an update. Klin.Padiatr. 217, 339-344
  • Lang, P., Greil J., Bader P., Schumm M., Handgretinger R., Klingebiel T., Schlegel P.G., Beck J.F., Scheel-Walter H.G. and Niethammer D. (2005) Bearbeitung und Transplantation hämatopoetischer Stammzellen. Ergebnisse und klinischer Nutzen der Stammzellaufreinigung von alternativen Spendern für die allogene Transplantation im Kindesalter. Monatsschrift Kinderheilkd. 153,954-964
  • Lang, P., Niethammer, D., Bader, P., and Greil, J. (2005) Comment on ‘CD34+ selected hematopoietic stem cell (HSC) not preceded by any immunosuppressive therapy as effective treatment of graft failure' - G Milone et al. Bone Marrow Transplant. 35, 522
  • Lang, P., Schumm, M., Greil, J., Bader, P., Klingebiel, T., Muller, I., Feuchtinger, T., Pfeiffer, M., Schlegel, P.G., Niethammer, D., and Handgretinger, R. (2005) A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients: preliminary results of a pilot study. Klin.Padiatr. 217, 334-338
  • Pfeiffer, M., Stanjevic, S., Feuchtinger, T., Greil, J., Handgretinger, R., Barbin, K., Jung, G., Martin, D., Niethammer, D., and Lang, P. (2005) Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation. Bone Marrow Transplant 36, 91-97
  • Lang P., Greil J., Bader P., Handgretinger R., Klingebiel T., Schumm M, Schlegel PG, Feuchtinger T., Pfeiffer M., Scheel-Walter H., Fuhrer M., Martin D., and Niethammer D. (2004) Long-term outcome after haploidentical stem cell transplantation in children. Blood Cell Mol Dis. 33, 281-287
  • Lang, P., Bader,P., Schumm,M., Feuchtinger,T., Einsele,H., Führer,M., Weinstock,C., Handgretinger,R., Kuci,S., Martin,D., Niethammer,D. and Greil,J. (2004) Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors. Br.J.Haematol., 124, 72-79
  • Lang, P., Griesinger A., Hamprecht K., Feuchtinger T., Schumm M., Neuhäuser F., Greil J., Martin D., Handgretinger R. and Niethammer D. (2004) Antiviral activity against CMV-infected fibroblasts in pediatric patients transplanted with CD34+-selected allografts from alternative donors. Human Immunology, 65, 423-431.
  • Lang, P., Handgretinger,R., Greil,J., Bader,P., Schumm,M., Klingebiel,T. and Niethammer,D. (2004) Transplantation of CD34+ enriched allografts in children with nonmalignant diseases: does graft manipulation necessarily result in high incidence of graft failure? Bone Marrow Transplant., 33, 125-126. Correspondence
  • Lang, P., Klingebiel,T., Bader,P., Greil,J., Schumm,M., Schlegel,P.G., Eyrich,M., Mueller-Weihrich,S., Niethammer,D. and Handgretinger,R. (2004) Transplantation of highly purified peripheral-blood CD34+ progenitor cells from related and unrelated donors in children with non-malignant diseases. Bone Marrow Transplant., 33, 25-32.
  • Lang, P., Klingebiel,T., Schumm,M., Handgretinger,R., Greil,J., Beck,J.F., Niethammer,D. and Bader,P. (2004) Correction of persistent thrombocytopenia by a boost of CD133+ selected stem cells in a patient transplanted for Wiskott-Aldrich syndrome 10 years ago. Bone Marrow Transplant., 33, 879-80. Correspondence
  • Lang, P., Pfeiffer,M., Handgretinger,R., Schumm,M., Demirdelen,B., Stanojevic,S., Klingebiel,T., Köhl,U., Kuci,S. and Niethammer,D. (2002) Clinical scale isolation of T cell-depleted CD56+ donor lymphocytes in children. Bone Marrow Transplant., 29, 497-502.
  • Lang, P., Schumm,M., Taylor,G., Klingebiel,T., Neu,S., Geiselhart,A., Kuci,S., Niethammer,D. and Handgretinger,R. (1999) Clinical scale isolation of highly purified peripheral CD34+progenitors for autologous and allogeneic transplantation in children. Bone Marrow Transplant., 24, 583-589.
  • Lang, P., Klein,R., Becker,E.W. and Berg,P.A. (1992) Distribution of the PBC-specific- (M2) and the naturally-occurring mitochondrial antigen- (NOMAg) systems in plants. Clin.Exp.Immunol., 90, 509-516.
  • Lang, P., Huenecke, S., Pfeiffer, M., Handgretinger, R. and Koehl, U. (2010) Natural killer cells in leukemia and tumor therapy. Monatsschr. Kinderh. 158, 223-226.
  • A complete list of publications can be viewed on publons.com by clicking on this link
  • ALL-SZT Forum 2012
  • Cooperative CWS-Studie
  • SAA-Studie
  • SIOP-EN (Société internationale d’oncologie pédiatrique, Neuroblastoma subgroup)
  • NHL-BFM
  • GPOH (Gesellschaft für pädiatrische Onkologie und Hämatologie)
  • DGKJ (Deutsche Gesellschaft für Kinder- und Jugendmedizin)
  • EBMT-PDWP (European Group for Blood and Marrow Transplantation, Working Party for Pediatric Diseases)